Did Conor McGregor really use ibogaine?

McGregor has publicly stated that ibogaine was part of his recovery from alcohol dependence, describing the experience as significant and crediting it with reducing his craving. His public account is consistent with what ibogaine does pharmacologically — GDNF-mediated interruption of alcohol dependence — though celebrity accounts of ibogaine typically omit the cardiac screening, medication taper requirements, continuous monitoring, and integration work that the full process involves.

What is ibogaine and why is it in the news because of McGregor?

Ibogaine is an alkaloid derived from Tabernanthe iboga, a shrub native to Central Africa, used for centuries in Bwiti ceremony and studied clinically since the 1960s for opioid and alcohol dependence. McGregor's public statements about using it for alcohol recovery brought mainstream attention to a medicine that decades of clinical research — including the 2023 Stanford study finding 88% reductions in PTSD symptoms and 87% in depression at one month — had not managed to generate at the same scale.

Where can I get ibogaine treatment?

Ibogaine is not available as a treatment in the United States — it has been Schedule I since 1970. The two primary destinations for Americans are Canada and Mexico. Canada does not list ibogaine under the Controlled Drugs and Substances Act, a meaningfully different legal position from Schedule I. At Transcend in Vancouver, BC, ceremony costs $2,000–$5,000 CAD — approximately $1,500–$3,700 USD — and Vancouver is roughly 45 minutes from the US border. Medical screening including EKG is required before every ceremony regardless of location.

Is ibogaine dangerous?

In a properly screened and continuously monitored setting, the risks are manageable. Ibogaine prolongs the QT interval in all participants — even those without pre-existing cardiac conditions — which is why continuous ECG monitoring and an on-site physician are mandatory throughout the 12–24 hour ceremony. In unscreened settings, this QT prolongation has triggered fatal arrhythmia. Historical estimates put serious adverse events at approximately 1 in 300 in unscreened populations. In screened and monitored programmes the rate is substantially lower — but not zero. The EKG requirement before every ceremony is not an administrative formality. It is what separates a manageable risk from a dangerous one.

What does the research show about ibogaine for alcohol and opioid addiction?

The GDNF mechanism underlying ibogaine's anti-addiction effect was confirmed in a 2005 Journal of Neuroscience study: infusing GDNF into the ventral tegmental area reproduced ibogaine's anti-alcohol effect; neutralising GDNF with antibodies eliminated it. No other currently available treatment acts on this pathway directly. Observational research on opioid dependence found 80% reported significant withdrawal reduction at time of treatment and 30% long-term abstinence without structured integration support — rising substantially in programmes with post-ceremony structure. The 2023 Stanford study found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans with treatment-resistant conditions.

Who should not use ibogaine after hearing about McGregor's story?

Absolute contraindications regardless of how compelling the account: QT prolongation or significant cardiac arrhythmia (ibogaine prolongs the QT interval — an EKG is required before every ceremony to identify this in advance); current SSRI or SNRI use without a completed supervised taper (serotonin syndrome risk is real and potentially fatal); methadone without a transition protocol; severe liver or kidney disease; active psychosis or schizophrenia spectrum disorder; lithium; most antipsychotics; and pregnancy. Someone in acute psychiatric crisis is also not an appropriate candidate — ibogaine amplifies what is present, not what the person hopes to find.

What does ibogaine ceremony actually involve — versus what McGregor described?

McGregor described an experience that interrupted his alcohol dependence. What that description typically omits: the mandatory EKG and cardiac screening required before ceremony; a supervised medication taper if on SSRIs or other serotonin-active drugs; 12–24 hours of continuous medical monitoring that a legitimate provider runs throughout the experience; a 2–3 day recovery period before travel is appropriate; and the integration work in the weeks after ceremony that determines whether any lasting change results. The ceremony is where the pharmacological interruption happens. Integration is where lasting change becomes possible — or not.

What happens after ibogaine ceremony and why does integration matter?

Ibogaine produces noribogaine — an active metabolite that remains pharmacologically present for weeks to months after ceremony. This sustains a period of elevated neuroplasticity during which new patterns are more accessible and existing ones more malleable. What is done during this window determines whether the ceremony produces lasting change. People who return immediately to the same environments, relationships, and unaddressed conditions that produced the problem typically find themselves back where they started within six weeks. Structured integration support — coaching, environmental changes, deliberate practice — is what uses that window effectively.

Is ibogaine available in Canada?

Ibogaine is not listed under Canada's Controlled Drugs and Substances Act — it is unscheduled rather than explicitly prohibited, a meaningfully different legal position from the United States (Schedule I) or the United Kingdom (Class A). It is not approved for medical use in Canada. Transcend operates in Vancouver, BC, and ibogaine ceremony costs $2,000–$5,000 CAD. Medical screening including EKG and blood panel is required before every ceremony. Vancouver is approximately 45 minutes from the US border.

Conor McGregor, Ibogaine, and What the Headlines Don't Cover

Conor McGregor has spoken publicly about ibogaine as part of his recovery from alcohol dependence. His statements brought more mainstream attention to ibogaine than six decades of clinical research had managed to generate. That attention has been useful and problematic in roughly equal measure.

Ibogaine is an alkaloid derived from Tabernanthe iboga, a shrub native to Central Africa. It interrupts alcohol and opioid dependence through a GDNF pathway that no other treatment directly addresses, and produces a 12–24 hour confrontational experience requiring continuous cardiac monitoring. Medical screening — including EKG — is required before any ceremony. It is not available as a treatment inside the United States.

Dense jungle canopy — ibogaine derives from Tabernanthe iboga, a shrub native to the forests of Central Africa — Photo via Pexels

What Conor McGregor Said About Ibogaine

McGregor has stated publicly that ibogaine was part of how he addressed alcohol dependence. He has described the experience in terms consistent with what the medicine actually does — a direct encounter with personal pattern, followed by a significant reduction in craving. The coverage that followed treated this primarily as a celebrity wellness story.

That framing is understandable and incomplete. What celebrity accounts of ibogaine typically convey: the ceremony happened, it was significant, and the person changed. What they typically do not convey: the mandatory cardiac screening, the supervised medication taper required for anyone on SSRIs or certain other drugs, the 12–24 hours of continuous medical monitoring, the 2–3 day recovery period before travel is appropriate, and the months of integration work that determine whether any lasting change results.

The ceremony is the beginning of a process, not the end of one. It is also the part that has the least bearing on long-term outcomes.

Why the Public Attention Is Both Useful and Not

Ibogaine has been studied since the 1960s. Howard Lotsof first documented its effect on opioid withdrawal in 1962. He filed US patents for its use in addiction treatment in 1985. The United States scheduled ibogaine as a controlled substance in 1970 — before any of this research existed — and the scheduling has not changed despite the clinical evidence that has accumulated since.

The 2023 Stanford study published in Nature Medicine found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month in 30 special operations veterans who had been through conventional treatment without adequate result. This did not generate a fraction of the mainstream press that McGregor's public statements did. The research community has been making a clinical case for ibogaine for thirty years. A single public figure saying it worked for him reached an audience that the studies had not.

The problem is that celebrity disclosure is not clinical guidance. It reaches people who may not be appropriate candidates — people with undiagnosed cardiac conditions, people on medications that cannot be safely combined with ibogaine, people in states of acute psychiatric instability that require a different form of support first. The people most determined to access ibogaine after reading about McGregor are not always the people for whom the risk profile is manageable.

What Ibogaine Actually Does — the Mechanism, Not the Story

Ibogaine acts on four receptor systems simultaneously. It binds kappa and mu-opioid receptors, interrupting withdrawal within 6–24 hours of administration. It acts on NMDA glutamate receptors, resetting hyperactive craving circuits. It acts on sigma-2 receptors, linked to remyelination and neural repair. It also inhibits the serotonin transporter — the same mechanism as SSRIs, which is why concurrent use creates a dangerous interaction.

The mechanism that matters most for alcohol and opioid dependence is GDNF — glial cell line-derived neurotrophic factor. A 2005 study in the Journal of Neuroscience confirmed that ibogaine's anti-addiction effect operates through GDNF upregulation in the ventral tegmental area: infusing GDNF directly into the VTA reproduced ibogaine's anti-alcohol effect, and neutralising GDNF with antibodies eliminated it. No other currently available treatment acts on this pathway directly.

The GDNF upregulation is sustained by noribogaine — ibogaine's primary active metabolite — which has a half-life of 28–49 hours and remains pharmacologically active for weeks to months after ceremony. This is the neuroplasticity window: a period during which new patterns are more accessible and existing ones more malleable. What is done during that window determines the long-term outcome.

Integration support is not a bonus service — it determines whether the ceremony produces lasting change. Providers who hand people a pamphlet and wish them luck are not providing ibogaine treatment. They are providing ibogaine. The distinction is not subtle.

Researcher in laboratory — the GDNF pathway mechanism behind ibogaine's anti-addiction effect was confirmed in a 2005 Journal of Neuroscience study — Photo by Edward Jenner via Pexels

The Research: What the Numbers Show

The 2023 Stanford study is the most cited piece of ibogaine research, but not the only one. It treated 30 special operations veterans with treatment-resistant PTSD, traumatic brain injury, and depression. Average reductions at one month: 88% in PTSD symptoms, 87% in depression, 81% in anxiety. The study documents what practitioners in this field had been observing for years — that ibogaine produces changes in this population that conventional approaches do not. Veterans who had been through programmes and prescriptions. People not naive about what standard treatment delivers. The 88% figure is striking in part because of the population: people who had already tried everything else.

Conventional antidepressant research considers a 50% reduction in depression scores a strong response. The Stanford numbers stand on their own with their caveats intact: 30 participants is not a definitive population, and the absence of a placebo arm is a genuine methodological limitation. Neither limitation changes the direction of the findings.

Following the Stanford study, Texas committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M University, and Baylor University. Colorado authorised five research sites. A 2026 executive order directed federal agencies to accelerate psychedelic research pathways. These are research processes — not treatment access for people seeking ibogaine now. Clinical trial enrollment requires meeting specific eligibility criteria and is measured in months, not days.

The fact that ibogaine research has been constrained by scheduling law for over 50 years is a policy failure, not a scientific verdict. The evidence that has accumulated despite those constraints is remarkably consistent in direction. The Stanford study and the research that followed came from a body of work that practitioners and researchers had been building since the 1960s, largely without the funding that a Schedule I classification makes structurally impossible.

Other Voices: Shawn Ryan, Joe Rogan, Bryan Hubbard

McGregor was not the first public figure to discuss ibogaine. Shawn Ryan — a former Navy SEAL and podcast host — has spoken about ibogaine as part of the conversation around treatment for combat-related PTSD and addiction in the veteran community. That conversation has been active longer than it reached mainstream coverage, partly because the need is acute: conventional treatment had not produced adequate results for a population facing real barriers to care.

Bryan Hubbard has written about ibogaine in the context of its traditional use and therapeutic applications. The Multidisciplinary Association for Psychedelic Studies has maintained an active ibogaine research programme and reference database for decades. Joe Rogan's podcast has featured multiple guests discussing ibogaine, its mechanism, and the clinical evidence behind it.

The consistent pattern across these public discussions: the pharmacological effect and the experience receive the attention. The screening requirements, contraindications, and integration process do not. The experience is the interesting part of the story. The safety infrastructure is not. And yet the safety infrastructure is what determines whether the experience is viable for a given person at all.

Who This Is Not For

Not everyone who hears about McGregor's experience is an appropriate candidate. Absolute contraindications — these apply regardless of provider, location, or how much a person wants access:

QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine prolongs the QT interval — this is the mechanism behind documented fatalities, and an EKG is required before every ceremony to identify it in advance.
Severe liver or kidney disease. Ibogaine is metabolised hepatically. Impaired clearance amplifies both therapeutic and adverse effects, including cardiac risk.
Active psychosis or schizophrenia spectrum disorder. Ibogaine amplifies what is present. It does not stabilise an unstable psychiatric state.
Current SSRI or SNRI use without a completed supervised taper. Ibogaine inhibits the serotonin transporter. The risk of serotonin syndrome is real and potentially fatal.
Methadone without a supervised transition protocol. Methadone's long half-life and cardiac effects require careful management before ceremony is possible.
Lithium and most antipsychotics.
Pregnancy.

Someone in acute psychiatric crisis is also not an appropriate candidate — regardless of how much they want access. The medicine tends to show people what they have been avoiding. Entering a 12–24 hour confrontational experience in a state of active destabilisation does not produce stability.

The full contraindications guide covers each condition in detail, including which are absolute and which require preparation rather than permanent disqualification. SSRIs are a conditional contraindication — a supervised taper removes the risk. Cardiac arrhythmia is not.

Is This Right for You?

If none of the above disqualifies you, the relevant question is not whether you found McGregor's account compelling. It is whether you are at a point where conventional options have been exhausted, whether you have the 5–7 days the process requires, and whether you have integration support in place for the weeks following ceremony.

At Transcend in Vancouver, ibogaine ceremony costs $2,000–$5,000 CAD. This includes an on-site medical professional, continuous cardiac monitoring throughout the 12–24 hours, the medicine, and facilitation. Vancouver is approximately 45 minutes from the US border — a practical consideration for Americans who cannot access ibogaine domestically. Integration coaching is available separately at $150–$300 CAD per session.

The FAQ addresses the most common questions about the process, cost, and candidacy. For more on what integration involves after ceremony, the integration page covers what the weeks following ceremony require. To begin a conversation about whether this is appropriate for your situation, apply through the application form. Every application receives a personal response within 2–3 business days. If the answer is no, we will say so directly.